Effective Sjögren’s management demands a strict separation between symptomatic relief for sicca and immunosuppression for ...
Andy Provencher spent a year searching for the cause of his exhausting symptoms before a physician's assistant suggested a ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...